Who are HBVAXPRO 5µg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Engerix-B Kinder, Vaccin GenHevac B Pasteur, HBV-MPL vaccine (208129), HBV-MPL vaccine, Engerix B® Pediatric, Henogen HB vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hbvaxpro-5-g.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

HBVAXPRO 5µg — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HBVAXPRO 5µg (HBVAXPRO 5µg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant hepatitis B vaccine. Area: Immunology / Infectious Disease.

phase 3 Recombinant hepatitis B vaccine Hepatitis B surface antigen (HBsAg) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

HBVAXPRO 5µg (HBVAXPRO 5µg) — Sanofi Pasteur, a Sanofi Company. HBVAXPRO is a recombinant hepatitis B surface antigen vaccine that stimulates the immune system to produce antibodies against hepatitis B virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
HBVAXPRO 5µg TARGET	HBVAXPRO 5µg	Sanofi Pasteur, a Sanofi Company	phase 3	Recombinant hepatitis B vaccine	Hepatitis B surface antigen (HBsAg)
Engerix-B Kinder	Engerix-B Kinder	GlaxoSmithKline	marketed	Recombinant hepatitis B vaccine	Hepatitis B surface antigen (HBsAg)
Vaccin GenHevac B Pasteur	Vaccin GenHevac B Pasteur	Central Hospital, Nancy, France	marketed	Recombinant hepatitis B vaccine	Hepatitis B surface antigen (HBsAg)
HBV-MPL vaccine (208129)	HBV-MPL vaccine (208129)	GlaxoSmithKline	phase 3	Recombinant hepatitis B vaccine with adjuvant	Hepatitis B surface antigen (HBsAg); TLR4 (via MPL adjuvant)
HBV-MPL vaccine	HBV-MPL vaccine	GlaxoSmithKline	phase 3	Recombinant hepatitis B vaccine with adjuvant	Hepatitis B surface antigen (HBsAg); TLR4 (via MPL adjuvant)
Engerix B® Pediatric	Engerix B® Pediatric	Sanofi Pasteur, a Sanofi Company	phase 3	Recombinant hepatitis B vaccine	Hepatitis B surface antigen (HBsAg)
Henogen HB vaccine	Henogen HB vaccine	Henogen	phase 3	Recombinant hepatitis B vaccine	Hepatitis B surface antigen (HBsAg)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant hepatitis B vaccine class)

Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
Central Hospital, Nancy, France · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Henogen · 1 drug in this class
VBI Vaccines Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HBVAXPRO 5µg — Competitive Intelligence Brief. https://druglandscape.com/ci/hbvaxpro-5-g. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing